首頁 > 市場調查報告書 > 製藥

藥物開發開發業務受託機關

生物製藥契約製造市場規模、佔有率和成長分析（按服務、類型、營運規模、原料、分子類型和地區分類）—產業預測（2026-2033 年）

市場調查報告書

商品編碼

1898254

生物製藥契約製造市場規模、佔有率和成長分析（按服務、類型、營運規模、原料、分子類型和地區分類）—產業預測（2026-2033 年）

Biopharmaceuticals Contract Manufacturing Market Size, Share, and Growth Analysis, By Service (Manufacturing, Formulation & Fill-Finish), By Type, By Scale Of Operation, By Source, By Molecule Type, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月16日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球生物製藥契約製造市場預計到 2024 年將達到 178.5 億美元，到 2025 年將達到 193.2 億美元，到 2033 年將達到 362.9 億美元，預測期（2026-2033 年）的複合年成長率為 8.2%。

由於新藥研發投資減少、先進技術普及、柔軟性增強以及創新產品上市速度加快，全球生物製藥契約製造市場預計將顯著成長。新建生產設施將提升產能，以滿足不斷成長的消費者需求。技術進步和創新的生物程序方法是關鍵促進因素，使合約服務供應商能夠應對生產成本高昂和批次轉移效率低等生產挑戰。此外，主要市場參與者之間的策略性收購、合併和聯盟正在推動全球對契約製造服務的需求不斷成長，從而增強市場成長並擴大生物製藥行業的產能。

推動全球生物製藥契約製造市場發展的因素

全球生物製藥契約製造市場預計將持續成長，這主要得益於幾個關鍵促進因素，包括學名藥需求的持續成長和研發活動的活性化。對先進技術投資的快速成長也促進了市場擴張。此外，生物療法需求的成長以及核醫領域的進步預計將進一步增強市場動態。特藥日益成長的重要性鞏固了這一上升趨勢，為全球生物製藥行業的研發和創新奠定了堅實的基礎，這有望在不久的將來改變市場格局。

限制全球生物製藥契約製造市場的因素

全球生物製藥契約製造市場面臨許多挑戰，可能阻礙其成長。其中，生產流程中的關鍵問題，特別是標籤不一致、包裝複雜和滅菌困難等，構成了重大障礙。此外，消費者信任度不足以及對生產流程缺乏了解也可能阻礙市場擴張。這些因素共同創造了一個不利於產業內潛在投資和合作的環境，最終影響生物製藥契約製造的整體發展和成功。相關人員需要解決這些問題，以創造更好的成長環境並增強市場信心。

生物製藥契約製造市場的全球趨勢

在全球生物製藥契約製造市場中，受技術進步和科學探索不斷深入的推動，市場呈現穩定上升的趨勢。人工智慧（AI）在生產現場的日益普及，提高了營運效率，並能夠更精準地分析複雜的生物過程和患者數據。這項技術變革不僅簡化了生產週期，還有助於實現個人化醫療，以滿足多樣化的治療需求。隨著相關人員日益認知到人工智慧驅動的創新在最佳化藥物研發和生產流程方面的潛力，在對高效生物製藥解決方案需求不斷成長的推動下，預計該市場將實現顯著成長。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Lonza（Switzerland）
Thermo Fisher Scientific Inc.（US）
WuXi Biologics（China）
Catalent, Inc.（US）
Samsung Biologics（South Korea）
Boehringer Ingelheim International GmbH（Germany）
Fujifilm Holdings Corporation（Japan）
AbbVie Inc.（US）
Eurofins Scientific（Luxembourg）
GenScript Biotech Corporation（China）
AGC Inc.（Japan）
Merck
KGaA（Germany）
JSR Corporation（Japan）
Stelis（India）
Recipharm AB（Sweden）
Emergent（US）
Shanghai Fosun Pharmaceutical Co., Ltd.（China）
Lotte Biologics（South Korea）
Hepalink Group（China）
Curia Global, Inc.（US）

結論與建議

簡介目錄

Product Code: SQSG35H2019

Global Biopharmaceuticals Contract Manufacturing Market size was valued at USD 17.85 Billion in 2024 and is poised to grow from USD 19.32 Billion in 2025 to USD 36.29 Billion by 2033, growing at a CAGR of 8.2% during the forecast period (2026-2033).

The global biopharmaceutical contract manufacturing market is poised for significant growth due to reduced investment for new drug development, access to advanced technologies, increased flexibility, and expedited market entry for innovative products. The establishment of new manufacturing facilities enhances production capacity to meet the rising consumer demand. Technological advancements and innovative bioprocessing methods are key drivers, enabling contract service providers to address manufacturing challenges such as high production costs and efficiency during batch transitions. Additionally, strategic acquisitions, mergers, and collaborations among prominent market players are fostering increased demand for contract manufacturing services worldwide, reinforcing market growth and expanding capabilities within the biopharmaceutical sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biopharmaceuticals Contract Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biopharmaceuticals Contract Manufacturing Market Segments Analysis

Global Biopharmaceuticals Contract Manufacturing Market is segmented by Service, Type, Scale Of Operation, Source, Molecule Type,TherapeuticArea and region. Based on Service, the market is segmented into Manufacturing, Formulation & Fill-Finish, Packaging & Labeling and Other Services. Based on Type, the market is segmented into Biologic Drug Substance Manufacturing and Biologic Drug Product Manufacturing. Based on Scale Of Operation, the market is segmented into Commercial Operations and Clinical Operations. Based on Source, the market is segmented into Mammalian Expression Systems and Non-Mammalian Expression Systems. Based on Molecule Type, the market is segmented into Monoclonal Antibodies, Cell & Gene Therapies, Antibody-Drug Conjugates, Vaccines, Therapeutic Peptides & Proteins and Other Molecule Types. Based on Therapeutic Area, the market is segmented into Oncology, Autoimmune Diseases, Metabolic Diseases, Cardiovascular Diseases, Neurology, Infectious Diseases and Other Therapeutic Areas. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Biopharmaceuticals Contract Manufacturing Market

The global biopharmaceuticals contract manufacturing market is poised for growth due to several key drivers, including the persistent increase in demand for generics and escalating research and development activities. A surge in investments focused on advanced technologies also contributes to market expansion. Additionally, the rising need for biological therapies, coupled with advancements in the nuclear medicine sector, is expected to further enhance market dynamics. The growing emphasis on specialty medicines serves to solidify this upward trajectory, positioning the global biopharmaceuticals landscape for robust development and innovation, which will likely transform the market in the foreseeable future.

Restraints in the Global Biopharmaceuticals Contract Manufacturing Market

The global biopharmaceuticals contract manufacturing market faces several challenges that may hinder its growth. Key issues related to the manufacturing process, including labeling inconsistencies, packaging complications, and difficulties in sterilization, are significant obstacles. Furthermore, a lack of consumer trust and limited knowledge regarding the manufacturing processes could also impede the market's expansion. These factors contribute to an environment that may deter potential investments and partnerships within the industry, ultimately affecting the overall development and success of biopharmaceutical contract manufacturing. Stakeholders must address these concerns to foster a more favorable growth landscape and enhance market confidence.

Market Trends of the Global Biopharmaceuticals Contract Manufacturing Market

The global biopharmaceuticals contract manufacturing market is witnessing a robust upward trend fueled by advancements in technology and increased scientific exploration. The growing integration of artificial intelligence (AI) within the manufacturing landscape is enhancing operational efficiencies, allowing for more accurate analysis of complex biological processes and patient data. This technological shift not only streamlines production cycles but also facilitates personalized medicine approaches, catering to a diverse range of therapeutic needs. As stakeholders increasingly recognize the potential of AI-driven innovations in optimizing drug development and manufacturing processes, the market is poised for significant growth, driven by rising demand for effective biopharmaceutical solutions.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Analysis
Regulatory Analysis
Patent Analysis
Case Studies
FDA Approved Biopharmaceuticals CMOs Centers

Global Biopharmaceuticals Contract Manufacturing Market Size by Service & CAGR (2026-2033)

Market Overview
Manufacturing
Formulation & Fill-Finish
Packaging & Labeling
Other Services

Global Biopharmaceuticals Contract Manufacturing Market Size by Type & CAGR (2026-2033)

Market Overview
Biologic Drug Substance Manufacturing
Biologic Drug Product Manufacturing

Global Biopharmaceuticals Contract Manufacturing Market Size by Scale Of Operation & CAGR (2026-2033)

Market Overview
Commercial Operations
Clinical Operations

Global Biopharmaceuticals Contract Manufacturing Market Size by Source & CAGR (2026-2033)

Market Overview
Mammalian Expression Systems
Non-Mammalian Expression Systems

Global Biopharmaceuticals Contract Manufacturing Market Size by Molecule Type & CAGR (2026-2033)

Market Overview
Monoclonal Antibodies
Cell & Gene Therapies
Antibody-Drug Conjugates
Vaccines
Therapeutic Peptides & Proteins
Other Molecule Types

Global Biopharmaceuticals Contract Manufacturing Market Size by Therapeutic Area & CAGR (2026-2033)

Market Overview
Oncology
Autoimmune Diseases
Metabolic Diseases
Cardiovascular Diseases
Neurology
Infectious Diseases
Other Therapeutic Areas

Global Biopharmaceuticals Contract Manufacturing Market Size & CAGR (2026-2033)

North America (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
- US
- Canada
Europe (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
- Brazil
- Rest of Latin America
Middle East & Africa (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Lonza (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi Biologics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalent, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Samsung Biologics (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fujifilm Holdings Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eurofins Scientific (Luxembourg)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GenScript Biotech Corporation (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AGC Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
JSR Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Stelis (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Recipharm AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shanghai Fosun Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lotte Biologics (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hepalink Group (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Curia Global, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments